Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field
The CD47 field faced setbacks earlier this year when Gilead’s magrolimab was hit with partial clinical holds, and another clinical hurdle can be added to the list, with AbbVie terminating a study of an antibody out of partner I-Mab.
The nixed study was exploring the IV drug lemzoparlimab in combination with or without an oral or IV formulation of dexamethasone and in combination with anti-myeloma regimens in adults with multiple myeloma. The trial began in January and had been slated for a July 2025 completion, but AbbVie ended up only enrolling eight patients with the white blood cell cancer out of an originally planned 163, according to the federal trials database.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.